Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference
A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.
About Vir Biotechnology
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Heartflow raises $316.7 million in US IPO as medtech listings attempt comeback
By Ateev Bhandari and Pritam Biswas (Reuters) -Medical technology firm Heartflow said on Thursday it had raised $316.7 million in its U.S. initial public offering, setting the stage for its Nasdaq debut in another test of investor appetite for medical tech companies. The Mountain View, California-based company sold 16.67 million shares at $19 each, compared with a targeted range of $17 to $18 apiece. It upsized its offering and raised the proposed range earlier this week reflecting strong demand. The IPO valued the company at $1.54 billion. U.S. IPOs have picked up pace in a much-awaited recovery, as solid tech earnings and progress on trade deals have helped restore investor confidence. Strong recent debuts mark a reversal from early April, when uncertainty around U.S. President Donald Trump's tariffs paused dealmaking. Heartflow's stock will begin trading on the Nasdaq on Friday under the "HTFL" ticker symbol. The closing of the offering is expected on August 11. J.P. Morgan, Morgan Stanley and Piper Sandler are the lead underwriters for the offering. Following software firm Figma's blowout debut last week, analysts expect companies with a compelling growth story to be welcomed by the public markets. "We expect Heartflow to be well received at launch, especially following Figma's breakout success, which has helped reset sentiment toward high-growth names," IPOX CEO Josef Schuster said. Bain Capital-backed Heartflow leverages AI to create 3D models of the heart via a single specialized scan, improving detection and treatment of coronary artery disease (CAD). As AI gains widespread acceptance, companies embedding it into workflows for meaningful use cases are catching investor attention, with the technology powering gains across various Big Tech businesses. Heartflow's revenue grew 39% for the quarter ended March 31 from a year earlier. Its platform to detect CAD was used in 132,000 patients in 2024. Sign in to access your portfolio
Business Upturn
32 minutes ago
- Business Upturn
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the 'Class Period'), of the important September 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Capricor class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 15, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants provided investors with material information concerning deramiocel, Capricor's lead cell therapy candidate drug for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants' statements included, among other things, Capricor's ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Further, defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. The lawsuit alleges this caused shareholders to purchase Capricor's securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Capricor class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ——————————- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
Yahoo
35 minutes ago
- Yahoo
Bitcoin price rallies as Trump plans to allow crypto into pension plans
Crypto prices saw an uplift on Thursday, rallying ahead of the expected signing of an executive order by US president Donald Trump, which would allow 401k pension plans to include so-called alternative assets such as bitcoin (BTC-USD). Bitcoin headed 1.7% higher on Thursday afternoon, to trade above the $116,000 mark. In recent weeks bitcoin has exceeded the $122,000 mark, pushing to all-time highs as the US allows crypto-friendly policies into law. Ethereum (ETH-USD), the second largest asset by market cap, also gained more than 6%, sitting around the $3,830 mark. Trump's executive order, expected to be signed around 12:00 pm ET on Thursday, according to Reuters, will direct the Securities and Exchange Commission (SEC) to facilitate the use of alternative assets in 401k plans and other retirement accounts. The order would mark a major shift in retirement investments, opening up the traditionally staid industry to more speculative and sometimes illiquid investments. Typically, most 401k participants are offered a mix of stock or bond funds or index products in which to invest. Read more: Lenders hold mortgage deals as Bank of England cuts interest rates Investment firms have put their weight behind the move, too. Both BlackRock (BLK) and KKR (KKR) have endorsed opening up the multitrillion-dollar retirement industry. "Private assets like real estate and infrastructure can lift returns and protect investors during market downturns," BlackRock chairman Larry Fink wrote in his latest annual investor letter. "We need to make it clear: Private assets are legal in retirement accounts. They're beneficial. And they're becoming increasingly transparent."
